The news of Cantor Fitzgerald raising the price target for Regeneron Pharmaceuticals while maintaining a Neutral rating indicates that the analyst sees potential for the stock's price to increase. However, the Neutral rating suggests that the analyst does not expect significant outperformance or underperformance relative to other stocks. This could lead to a neutral impact on the stock's price in the short term.